Probability of EFS by patient subgroup
| Global population . | No. of patients . | EFS % (SE) . | P value . |
|---|---|---|---|
| Risk stratification | 482 | 55 (2.6) | |
| SR | 99 | 63 (5.6) | .021 |
| HR | 383 | 53 (2.9) | .021 |
| Age | |||
| <1 y | 63 | 58 (6.3) | .91 |
| 1-2 y | 52 | 58 (7.8) | .91 |
| 2-10 y | 181 | 55 (4.6) | .91 |
| >10 y | 186 | 57 (4.0) | .91 |
| WBC count (×109/L) | |||
| <10 | 171 | 60 (4.4) | .0001 |
| 10-99 | 236 | 57 (3.7) | .0001 |
| >100 | 75 | 37 (5.7) | .0001 |
| FAB types | |||
| M0 | 34 | 49 (8.9) | .12 |
| M1 | 88 | 44 (6.5) | .12 |
| M2 | 91 | 64 (5.8) | .12 |
| M4 | 83 | 64 (5.7) | .12 |
| M5 | 117 | 54 (5.6) | .12 |
| M6 | 5 | 100 (/) | .12 |
| M7 | 44 | 56 (7.7) | .12 |
| Unclassifiable/not known | 20 | 41(14.5) | .12 |
| Subgroups | |||
| FLT3 Pos overall | 52 | 47 (7,5) | |
| FLT3-ITD Pos | 42 | 47 (8.6) | |
| FLT3-ALM (D835/I836) Pos | 10 | 47 (6.7) | |
| FLT3-ITD Pos vs FLT3-ITD Neg | .22 | ||
| 11q23 abnormalities other than t(9;11) | 46 | 52 (10.1) | |
| 11q23 abnormalities other than t(9;11) vs other | .58 | ||
| t(9;11) | 19 | 61 (11.6) | |
| t(9;11) vs other | .78 | ||
| Monosomal karyotype | 10 | 20 (12.6) | |
| Monosomal karyotype vs other karyotype | .0002 | ||
| Complex karyotype | 27 | 40 (9.6) | |
| Complex karyotype vs other karyotype | .048 | ||
| NPM mutations Pos | 14 | 64 (15.2) | |
| NPM Pos vs NPM Neg | .24 | ||
| CEBPα mutations Pos | 18 | 60 (12.9) | |
| CEBPα Pos vs Neg | .33 |
| Global population . | No. of patients . | EFS % (SE) . | P value . |
|---|---|---|---|
| Risk stratification | 482 | 55 (2.6) | |
| SR | 99 | 63 (5.6) | .021 |
| HR | 383 | 53 (2.9) | .021 |
| Age | |||
| <1 y | 63 | 58 (6.3) | .91 |
| 1-2 y | 52 | 58 (7.8) | .91 |
| 2-10 y | 181 | 55 (4.6) | .91 |
| >10 y | 186 | 57 (4.0) | .91 |
| WBC count (×109/L) | |||
| <10 | 171 | 60 (4.4) | .0001 |
| 10-99 | 236 | 57 (3.7) | .0001 |
| >100 | 75 | 37 (5.7) | .0001 |
| FAB types | |||
| M0 | 34 | 49 (8.9) | .12 |
| M1 | 88 | 44 (6.5) | .12 |
| M2 | 91 | 64 (5.8) | .12 |
| M4 | 83 | 64 (5.7) | .12 |
| M5 | 117 | 54 (5.6) | .12 |
| M6 | 5 | 100 (/) | .12 |
| M7 | 44 | 56 (7.7) | .12 |
| Unclassifiable/not known | 20 | 41(14.5) | .12 |
| Subgroups | |||
| FLT3 Pos overall | 52 | 47 (7,5) | |
| FLT3-ITD Pos | 42 | 47 (8.6) | |
| FLT3-ALM (D835/I836) Pos | 10 | 47 (6.7) | |
| FLT3-ITD Pos vs FLT3-ITD Neg | .22 | ||
| 11q23 abnormalities other than t(9;11) | 46 | 52 (10.1) | |
| 11q23 abnormalities other than t(9;11) vs other | .58 | ||
| t(9;11) | 19 | 61 (11.6) | |
| t(9;11) vs other | .78 | ||
| Monosomal karyotype | 10 | 20 (12.6) | |
| Monosomal karyotype vs other karyotype | .0002 | ||
| Complex karyotype | 27 | 40 (9.6) | |
| Complex karyotype vs other karyotype | .048 | ||
| NPM mutations Pos | 14 | 64 (15.2) | |
| NPM Pos vs NPM Neg | .24 | ||
| CEBPα mutations Pos | 18 | 60 (12.9) | |
| CEBPα Pos vs Neg | .33 |
ALM, activating loop mutations; CEBPα, CCAAT/enhancer binding protein; ITD, internal tandem duplication; Neg, negative; NPM, nucleophosmin; Pos, positive; Boldface P values denote statistically significant differences (<.05).